Understand the source comparison
Mechanisms of Action: Neurotrophic Stimulation vs Amyloid Clearance
Cerebrolysin functions as a neurotrophic factor analog. Its peptide fragments (molecular weight <10 kDa) cross the blood-brain barrier and bind to TrkB receptors (the same receptors activated by BDNF), triggering intracellular signaling cascades that promote d
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin functions as a neurotrophic factor analog. Its peptide fragments (molecular weight <10 kDa) cross the blood-brain barrier and bind to TrkB receptors (the same receptors activated by BDNF), triggering intracellular signaling cascades that promote dendritic branching, synaptogenesis, and long-term potentiation. Animal studies published in the Journal of Neural Transmission have demonstrated that cerebrolysin upregulates synapsin I and synaptophysin expression, both critical for synaptic vesicle trafficking. The mechanism is endogenous pathway amplification. You're not introducing a foreign therapeutic agent so much as mimicking signals the brain already uses for repair.
- Aducanumab operates through a completely different mechanism: selective immunotargeting of aggregated amyloid-beta. The antibody recognizes a conformational epitope present on fibrillary Aβ and soluble oligomers but shows minimal binding to monomeric Aβ. Once bound, the antibody-antigen complex is phagocytosed by microglia via Fc receptor engagement. Essentially recruiting the brain's immune cells to clear plaques. The EMERGE and ENGAGE Phase III trials showed dose-dependent reductions in amyloid PET signal, though clinical efficacy remains contested. The cerebrolysin vs aducanumab mechanism difference matters: cerebrolysin works whether plaques are present or not; aducanumab requires existing amyloid deposits to bind.